Crossref
The antagonist SPECT tracer 123I-iododexetimide binds preferentially to the muscarinic M1 receptor in-vivo, but is it also a potential tool to assess the occupancy of muscarinic M1 receptors by agonists?
Receptors & Clinical Investigation · 2016
DOI: 10.14800/rci.1163 ↗Kurz gefasst
Fachartikel in der Zeitschrift Receptors & Clinical Investigation, 2016.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
(2016). The antagonist SPECT tracer 123I-iododexetimide binds preferentially to the muscarinic M1 receptor in-vivo, but is it also a potential tool to assess the occupancy of muscarinic M1 receptors by agonists?. Receptors & Clinical Investigation. https://doi.org/10.14800/rci.1163
Vancouver
The antagonist SPECT tracer 123I-iododexetimide binds preferentially to the muscarinic M1 receptor in-vivo, but is it also a potential tool to assess the occupancy of muscarinic M1 receptors by agonists?. Receptors & Clinical Investigation. 2016. doi:10.14800/rci.1163
BibTeX
@article{euvimed2016,
title = {The antagonist SPECT tracer 123I-iododexetimide binds preferentially to the muscarinic M1 receptor in-vivo, but is it also a potential tool to assess the occupancy of muscarinic M1 receptors by agonists?},
journal = {Receptors & Clinical Investigation},
year = {2016},
doi = {10.14800/rci.1163}
}
EUVIMED